الصفحة الرئيسية>>Signaling Pathways>> TGF-β / Smad Signaling>> SMAD>>Disitertide (P144)

Disitertide (P144)

رقم الكتالوجGC34060

Disitertide (P144) (P144) عبارة عن مثبط هضمي لعامل النمو المحول بيتا 1 (TGF-β ؛ 1) مصمم خصيصًا لمنع التفاعل مع مستقبله. Disitertide (P144) (P144) هو أيضًا مثبط PI3K ومحفز موت الخلايا المبرمج.

Products are for research use only. Not for human use. We do not sell to patients.

Disitertide (P144) التركيب الكيميائي

Cas No.: 272105-42-7

الحجم السعر المخزون الكميّة
1mg
79٫00
متوفر
5mg
315٫00
متوفر
10mg
504٫00
متوفر
25mg
1035٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Disitertide is an inhibitor of TGF-β1.

Disitertide (P144) prevents TGF-β1-dependent inhibition of MV1Lu proliferation in vitro and markedly reduces binding of TGF-β1 to its receptors. Disitertide blocks TGF-β1-dependent stimulation of a reporter gene under the control of human α2(I) collagen promoter[1].

Treatment with Disitertide at low doses causes a significant inhibition of HSC activation and a marked reduction in liver fibrosis in a rat model of chronic exposure to CCl4. A dose as low as 70 μg of the 15-mer peptide Disitertide, given to rats (300 g body weight) on alternate days, decreases fibrogenesis significantly during chronic exposure to CCl4[1].

[1]. Ezquerro IJ et al. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine. 2003 Apr;22(1-2):12-20.

مراجعات

Review for Disitertide (P144)

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Disitertide (P144)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.